

INVESTOR Presentation

AUGUST 2021

heranba.co.in

Safe Harbor

This presentation and the accompanying slides (the "Presentation"), which have been prepared by Heranba Industries Limited (the "Company"), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in connection with any contract or binding commitment what so ever. No offering of securities of the Company will be made except by means of a statutory offering document containing detailed information about the Company.

This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded

Certain matters discussed in this Presentation may contain statements regarding the Company's market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. These risks and uncertainties include, but are not limited to, the performance of the Indian economy and of the economies of various international markets, the performance of the industry in India and world-wide, competition, the company's ability to successfully implement its strategy, the Company's future levels of growth and expansion, technological implementation, changes and advancements, changes in revenue, income or cash flows, the Company's market preferences and its exposure to market risks, as well as other risks. The Company's actual results, levels of activity, performance or achievements could differ materially and adversely from results expressed in or implied by this Presentation. The Company assumes no obligation to update any forward-looking information contained in this Presentation. Any forward-looking statements and projections made by third parties included in this Presentation are not adopted by the Company and the Company is not responsible for such third-party statements and projections.

CONTENTS



COMPANY OVERVIEW SLIDE 04

02

MANAGEMENT TEAM

QUARTERLY PERFORMANCE

04

03











HERANBA AT GLANCE SLIDE 05

OUR JOURNEY SLIDE 06


VALUE CHAIN SLIDE 07

INTERMEDIARIES SLIDE 08

TECHNICALS SLIDE 09

FORMULATIONS SLIDE 10

HERANBA at a Glance



	(A)	
3 Manufacturing Facilities	60 + Countries Presence	650+ Employees (as of FY21)
81.05% Revenue from Institutional customers ^{**} (as of FY21)	9400+ Dealers across India	47.66% Revenue from Exports as % of sales (as of FY21)
22.61% Revenue from Top 10 customers (as of FY21)	36.33% ROE [#] (as of FY21)	

Our Journey




CMAC

 Started manufacturing the Intermediate CMAC



TECHNICALS

 Forward integrated into the manufacturing of Technicals, primarily made from the raw material CMAC and other Intermediates





INITIAL PUBLIC OFFERING

Listed on BSE & NSE



TURNOVER

Achieved Turnover of ₹500 Crores

Value Chain


Value Chain



HIL over the years, has scaled up the manufacturing of Intermediates, Technicals and Formulations which form part of the entire value chain of the agrochemicals industry

Manufacturing Process

- HIL manufactures a wide range of products and each product has its own unique manufacturing process
- The Company specialises in the manufacturing processes that mainly include chemical reactions of:





Intermediaries

Intermediates		
Cypermethric Acid Chloride (CMAC)	High CIS CMA	
High CIS CMAC	High Trans CMA	
High Trans CMAC	Bromobenzenes	
Metaphenoxy Benzaldehyde (MPBD)	End-use Intermediates manufactured are for Company's own captive consumption for manufacturing various Technicals and Formulations	

Technicals

Insecticides

- Cypermethrin
- Deltamethrin
- Alpha Cypermethrin
- Acephate
- Lambda Cyhalothrin
- Permethrin
- Profenophos
- Temephos
- Theta Cypermethrin
- Thiamethoxam
- Imidacloprid

Herbicides

- Glyphosate
- Metribuzin
- Clodinofop

Technicals

Fungicides

- Tricyclazole
- Hexaconazole



Formulations

Insecticides

- Jayam
- Progress Plus
- Param
- Cypraplus
- Dyken
- Mantra
- Astron
- Signor
- Prompt
- Cypra
- Heraban
- Alpha Shakti
- Henoxa

Herbicides

Fungicides

Sulphy

Mask

Mandy

Macamba
Propizole


Vintage

Exort

Tulip

- Glory Glory 71
- Chakde Shera
- Heraquat Pendant
- Zinta Atria

Revenue from Technical and Formulations



"Technicals includes Technical Domestic and Technical Exports | "Formulations includes Branded Formulations, Formulation Exports and Public Health



ABOUT PROMOTERS SLIDE 12

LEADERSHIP TEAM SLIDE 13

02 MANAGEMENT

Experienced Promoters with Domain Knowledge

Promoters having a cumulative experience of more than six decades



Mr. Sadashiv K. Shetty

CHAIRMAN AND EXECUTIVE DIRECTOR

- Holds a bachelor's (physics and chemistry) and master's (chemistry) degree in science from University of Mysore
- Has experience of more than three decades in agrochemicals industry
- Has been on Board since September, 1994 and is responsible for the overall supervision, direction and management of the Company
- He has been instrumental in new products development and addition of capacities
- Has previously worked with Sudarshan Chemical Limited, Gharda Chemical Limited, Hoechst Pharmaceuticals and Nirlon Limited



Mr. Raghuram K. Shetty

MANAGING DIRECTOR

- Holds a bachelor's degree in economics from University of Mysore
- Subsequently, pursued government commercial diploma from the Department of Education, Bureau of Government Examinations, Maharashtra and completed diploma in export and import management from the India International Trade Centre, Mumbai
- Has experience of more than three decades in agrochemicals industry
- Has been on Board since September, 1994 and is fully involved in day-to-day affairs of the Company
- He has been instrumental in developing export business for the Company

Management Expertise

Mr. Rajkumar Bafna

CHIEF FINANCIAL OFFICER

- Holds a bachelor's degree in commerce from University of Bombay and is an associate member of the Institute of Chartered Accountants of India
- He has 18+ years of industry experience in the field of accounts, corporate finance and management information systems
- Oversees overall finance and accounting, risk management and audit compliance in the Company

Mr. Rajesh Ohri

VICE PRESIDENT - PROCUREMENT & BUSINESS DEVELOPMENT

- Holds a bachelor's degree in engineering (production) from Shivaji University, Kolhapur
- He has several years of experience in field of supply chain management and procurement of raw materials
- Looks after procurement department along with business development function of the Company

Mr. Mopidevi V. Rao

HEAD OF R&D DIVISION

- Holds a bachelor's and master's degree (organic chemistry) degree in science from Andhra University
- He has also done Ph.D. in chemistry from GITAM University
- He has experience of more than two decades in the field of agro formulations of insecticides, fungicides and herbicides
- Looks after development of new products & has control over the R&D activities in the Company
- Has previously been associated with Insecticides (India) Limited, Nagarjuna Agrichem Limited and Solaris Chemtech Limited



FINANCIAL HIGHLIGHTS

KEY RATIOS

FINANCIAL SUMMARY


Q1FY22 Financial Highlights

Total Income at ₹3556.79 million in Q1FY22 as compared to ₹2692.79 million in Q1FY21 – growth of 32.09% Y-o-Y and growth of 30.20% Q-o-Q. EBITDA (incl. other income) at ₹690.91 million in Q1FY22 as compared to ₹435.66 million in Q1FY21 – growth of 58.59% Y-o-Y and growth of 9.59% Q-o-Q.

EBITDA (incl. other income) Margins were at 19.66% in Q1FY22 as compared to 16.19% in Q1FY21 – growth of approx. 348bps Y-o-Y and de-growth of 388bps Q-o-Q.

Profit After Tax at ₹473.87 million in Q1FY22 as compared to ₹285.83 million in Q1FY21 – growth of 65.79% Y-o-Y and growth of 9.69% Q-o-Q.

Quarterly Performance



Profit & Loss Summary

			(₹ IN MILLION)
PARTICULARS	Q1FY21	Q4FY21	Q1FY22
Revenue from Operations	2,691.65	2,678.30	3,514.06
Other Income	1.14	53.46	42.73
Total Revenue	2,692.79	2,731.76	3,556.79
Total Expenses	2,304.71	2,154.21	2913.69
Profit Before Tax	388.08	577.55	643.10
Total Tax Expense	102.25	145.55	169.23
Profit After Tax	285.83	432.00	473.87
EPS Basic (₹)	7.32	11.04	11.84
EPS Diluted (₹)	7.32	11.04	11.84
EBITDA (incl. Other income)	435.66	630.46	690.91
EBITDA (incl. Other income) Margin	16.19%	23.54%	19.66%




KEY RATIOS SLIDE 19

FINANCIAL SUMMARY

SLIDE 21


Performance


KEY Ratios



Business Mix

Diversified customers base across geographies helps to mitigate risks and benefit from expected growth in agrochemical market





Revenue from Exports

Profit & Loss Summary

			(₹ IN MILLION)
PARTICULARS	FY19	FY20	FY21
Revenue from Operations	10,044.44	9,513.74	12,186.47
Other Income	73.94	165.32	70.30
Total Revenue	10,118.38	9,679.06	12,256.77
Total Expenses	8,897.18	8,390.64	10,173.92
Profit Before Tax	1,221.2	1,288.42	2,082.85
Total Tax Expense	467.18	311.85	540.59
Profit After Tax	754.02	976.57	1,542.26
EPS Basic (₹)	19.31	25.00	39.41
EPS Diluted (₹)	19.31	25.00	39.41
EBITDA (incl. Other Income)	1,388.07	1,458.82	2,283.69
EBITDA (incl. Other Income) Margin	13.82%	15.33%	18.74%

Balance Sheet (1/2)

			(₹ IN MILLION)
PARTICULARS	FY19	FY20	FY21
Non-Current Assets			
Property, plant and equipment	511.39	954.41	1,334.35
Capital work-in-progress	159.70	377.72	96.95
Financial Assets:			
(i) Investments	0.24	37.31	100.98
(ii) Other Financial Assets	71	84.27	241.71
Current tax assets (Net)	1.48		10.20
Other non-current assets	344.58	80.66	97.01
Total Non-Current Assets (I)	1,088.39	1,534.37	1,881.20
Current Assets			
Inventories	1,138.94	1,455.18	1,659.86
Financial Assets:			
(i) Trade Receivables	2,532.72	2,584.67	3,417.62
(ii) Cash and cash equivalents	209.65	31.94	847.80
(iii) Loans	0	8.95	
(iv) Other financial assets	15.4	17.17	19.97
Other current assets	619.33	615.35	606.68
Total Current Assets (II)	4,516.04	4,713.26	6,551.93
Total Assets (I + II)	5,604.43	6,247.63	8,433.13

Balance Sheet (2/2)

			(₹ IN MILLION)
PARTICULARS	FY19	FY20	FY21
Equity and liabilities			
Equity			
Equity share capital	390.56	390.56	400.13
Other equity	1891.2	2817.93	4881.21
Total Equity	2281.76	3208.49	5281.34
Liabilities			
Non-Current Liabilities			
Financial Liabilities			
(i) Borrowings			
(ii) Other Financial Liabilities	57.27	61.46	66.41
Provisions	4.22	6.49	22.43
Other Non-current liabilities		2.28	11.71
Deferred Tax balances (net)	41.27	16.09	
Total Non-Current Liabilities (I)	102.76	86.32	100.55
Current Liabilities			
Financial Liabilities			
(i) Borrowings	498.74	430.79	502.79
(ii) Trade payables	2352.07	2124.68	1955.82
(iii) Other Financial Liabilities	121.89	139.30	283.27
Current tax Balances (net)	101.68	37.46	88.37
Other current liabilities	96.46	163.19	159.73
Provisions	49.07	57.40	61.25
Total Current Liabilities (II)	3219.91	2952.82	3051.24
Total Liabilities (I + II)	3322.67	3039.14	3151.79
TOTAL EQUITY AND LIABILITIES	5604.43	6247.63	8433.13

Cashflow Statement


			(₹ IN MILLION)
PARTICULARS	FY19	FY20	FY21
Cash Flow from Operations	877.02	542.11	603.98
Cash Flow from Investing Activities	-373.79	-520.39	-407.13
Cash Flow from financing Activities	-411.35	-199.43	619.01
Net increase/ (decrease) in cash and cash equivalents	91.88	-177.71	815.86
Cash and cash equivalents at beginning of the year	117.77	209.65	31.94
Cash and cash equivalents at end of the year	209.65	31.94	847.80



COMPETITIVE STRENGTHS

BUSINESS STRATEGY

Competitive Strengths



Business Strategy

Well positioned to exploit opportunities offered by growth in pyrethroids market.



Entering Highly Regulated USA and Europe markets

Strengthening of R&D Facility Enhancing Production Capabilities Enhancing Formulation & Technicals in International Markets Branded Formulations and Public Health

THANK YOU

CONTACT US:

Investor Relations Nikhil Morye | Kanav Khanna nmorye@christensenir.com kkhanna@christensenir.com

CORPORATE OFFICE

Heranba Industries Ltd. 101/102, Kanchanganga, Factory Lane, Borivali (W), Mumbai – 400 092, India

Tel: 91-22-2898 7912/14, 91-22-2898 2133/44, 91-22-2898 4439, 91-22-5070 5050

Email : compliance@heranba.com

